References
- Zolg JW, Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol Mol Cell Proteomics 2004;3:345–54.
- Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nature Rev Cancer 2005;5:142–9.
- Poste G. Bring on the biomarkers. Nature 2011;469:156–7.
- Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol 2002;2:4. doi: 10.1186/1471-2288-2-4.
- Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008;2:1386–402.
- Rifai N, Gilette MA, Carr S. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnol 2006;24:971–83.
- Sprung RW, Brock JW, Tanksley JP, Li M, Washington MK, Slebos RJ, Liebler DC. Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics 2009;8:1988–98.
- Heaton KJ, Master SR. Peptide extraction from formalin-fixed paraffin-embedded tissue. Curr Protocols Protein Sci 2011;65:23.5. doi: 10.1002/0471140864.ps2305s65.
- Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnol 2008;26:1367–72.
- Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 2014;13:2513–26.